Search results
Showing 1 to 5 of 5 results for siponimod
Siponimod for treating secondary progressive multiple sclerosis (TA656)
Evidence-based recommendations on siponimod (Mayzent) for treating secondary progressive multiple sclerosis in adults.
Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)
Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.
Tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis ID6351
In development Reference number: GID-TA11333 Expected publication date: TBC
Ofatumumab for treating relapsing multiple sclerosis (TA699)
Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.
Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.